Q. Zhang

Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy

Xinmei Kang, Q. Zhang, S. Wang et al. · Canadian Medical Association Journal · 2010 · 140 citations · Full text

ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R²‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma

Umberto Vitolo, Thomas E. Witzig, Randy D. Gascoyne et al. · Hematological Oncology · 2019 · 84 citations

Surgical Oncology, Cd20+ Abc-type Dlbcl, Immunodeficiencies +22

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Ye Guo, Myung‐Ju Ahn, Anthony T.�C. Chan et al. · Annals of Oncology · 2019 · 57 citations · Full text

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, Mariana Chávez‐MacGregor et al. · Annals of Oncology · 2022 · 57 citations · Full text

Endocrine Oncology, Vs Physician Choice, Advanced/metastatic Breast Cancer +11

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

B. Xu, Tao Sun, Q. Zhang et al. · Annals of Oncology · 2020 · 43 citations

Breast Oncology, Oncology, Capecitabine Versus Capecitabine +7